// App-Quantinova.ai

: Cabozantinib + nivolumab in adult patients with advanced or metastatic renal cell carcinoma: A retrospective, non-interventional study in a real-world cohort.

Researchers

Presenter

  • Thomas Hilser

Principal Investigators

  • Christopher Darr

  • Guenter Niegisch

  • Marco Julius Schnabel

  • Susan Foller

  • Lorine Haeuser

  • Stefanie Zschaebitz

  • Jonas Lewerich

  • Merle Anders-Meyn

  • Philipp Ivanyi

  • Katrin Schlack

  • Viktor Grünwald

Medical Centers

  • University Hospital, Dept. of Urology, Essen, Germany

  • National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany

  • Klinik für Urologie der Universität Regensburg am Caritas-Krankenhaus St. Josef, Regensburg, Germany

  • Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany

  • 3rd Medical Department,Klinikum rechts der Isar der Technischen Universität München,München,Germany

  • Marien Hospital Herne, University hospital of University Bochum, Department for urology, Bochum, Germany

  • Urology Department, Dusseldorf University Hospital, Medical Faculty, Heinrich-Heine-University, Dusseldorf, Germany

  • Universitätsklinikum Essen (AöR), Westdeutsches Tumorzentrum Essen, Innere Klinik (Tumorforschung), Essen, Germany

  • Medizinisch Hochschule Hannover, Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Hannover, Germany

  • Münster University Hospital, Münster, Germany

  • Urology Department, Jena University Hospital, Jena, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

  • Nivolumab

Outcome

  • N/A

Study Design

  • Non Interventional

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved